Skip to search formSkip to main contentSkip to account menu

CPI-0004Na

Known as: CPI0004Na 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Preclinical Toxicity, Toxicokinetics, and Antitumoral Efficacy Studies of DTS-201, a Tumor-Selective Peptidic Prodrug of Doxorubicin
Purpose: There is a clear clinical need for cytotoxic drugs with a lower systemic toxicity. DTS-201 (CPI-0004Na) is a peptidic… 
2006
2006
Thimet oligopeptidase (EC 3.4.24.15) activates CPI-0004Na, an extracellularly tumour-activated prodrug of doxorubicin.
2004
2004
CPI-0004Na, a new doxorubicin prodrug, reduces growth of 3LL-H61 carcinoma lung metastases in C57BI/6 mice.
The ETAP concept (Extracellularly Tumor-Activated Prodrug) is a new approach developed to overcome the lack of selectivity and… 
2003
2003
CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10…
Traditional chemotherapeutic drugs are often restricted by severe side effects and lack of tumor specificity. Peptide prodrugs… 
2003
2003
CD 10 Is a Key Enzyme Involved in the Activation of Tumor-activated Peptide Prodrug CPI-0004 Na and Novel Analogues : Implications for the Design of Novel Peptide Prodrugs for the Therapy of CD 10…
Traditional chemotherapeutic drugs are often restricted by severe side effects and lack of tumor specificity. Peptide prodrugs… 
2002
2002
CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
The search for cancer therapies that are more selective for tumor cells and spare normal sensitive cells has been very active for… 
2002
2002
CPI-0004 Na , a New Extracellularly Tumor-Activated Prodrug of Doxorubicin : In Vivo Toxicity , Activity , and Tissue Distribution Confirm Tumor Cell Selectivity 1
The search for cancer therapies that are more selective for tumor cells and spare normal sensitive cells has been very active for… 
2002
2002
Improved activity of CPI-0004Na, a new doxorubicin prodrug, in an experimental metastasis model
2000
2000
CPI-0004Na An extracellularly tumor-activated prodrug of doxorubicin
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)